Genix Pharmaceuticals Issues Clarification to Previously Announced Private Placement Terms
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") wishes to clarify an error in its news release dated September 04, 2025, regarding the Company's recently closed non-brokered private placement.The previous release incorrectly stated that the Units were issued at a price of $0.10 per Unit. The correct issue price was $0.05 per Unit.Accordingly, the Company issued 2,000,000 units (each, a "Unit") at a...
2025-10-07 5:48 PM EDT
Genix Pharmaceuticals Closes Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2025) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces that it has closed its previously announced non-brokered private placement raising gross proceeds of $100,000. The Company has issued 2,000,000 units (each a "Unit") at a price of $0.10 per Unit. Each Unit consists of one common share of the Company (a "Share") and one transferable common share purchase warrant (a "Warrant"). Each Warrant...
2025-09-04 4:15 PM EDT
Genix Announces TSX-V Approval of Warrant Amendments
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants").The current exercise price of...
2024-02-06 1:29 PM EST
Genix Announces Warrant Repricing and Seeks Extension
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend the exercise price, the warrant accelerator terms and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants").The Corporation is proposing to reduce the exercise price of the warrants from $0.30...
2024-01-18 6:05 PM EST
Genix Announces AGM Results
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") is pleased to report the results of the Annual General Meeting of shareholders held on May 18, 2023 (the "AGM"). Each of the director nominees proposed by management for election were elected to the Board of Directors: Sina Pirooz, Mahmoud Aziz, Kevin Bottomley, Jamie Lewin, and Paul Chow. In addition, the following resolutions presented below...
2023-05-26 4:27 PM EDT
Genix Receives Approval to Extend Warrants from the TSX Venture Exchange
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has received approval from the TSX Venture Exchange (the "Exchange") to extend 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months (see July 20, 2022 press release).In addition, Genix would like to provide a correction to the expiry date on 1,218,333 warrants as published...
2022-07-28 8:45 AM EDT
Genix Proposes to Extend Warrants
Vancouver, British Columbia--(Newsfile Corp. - July 20, 2022) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants") by eighteen (18) months. 2,136,612 warrants which are set to expire on July 24, 2022 will be extended to January 24, 2024. These Warrants...
2022-07-20 8:45 AM EDT
Genix Pharmaceuticals Corp. Receives Approval for Drug Establishment License
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") Genix is pleased to announce that, pursuant to a Health Canada Drug Establishment License (DEL) inspection, carried out at its warehouse premises on June 22, 2021, the Company has now received a Notice of Compliant Rated Inspection with a compliant (C) rating. This rating means that at the time of the inspection, its activities were fully in...
2021-07-15 8:47 AM EDT
Genix Pharmaceuticals Corp. Lists on the OTCQB Venture Market Exchange
Vancouver, British Columbia--(Newsfile Corp. - June 21, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company) is pleased to announce that it has received approval to begin trading its common shares on the OTC Markets Group's OTCQB Venture Market in the United States under the symbol "GENPF". The Company's common shares will begin trading on the OTCQB Marketplace today, June 21st, 2021 and will continue to trade on the TSX Venture Exchange under the...
2021-06-21 8:30 AM EDT
Genix Pharmaceuticals Corporation Provides a Corporate Update to Shareholders
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("Genix" or the "Company"). President, Mr. Mahmoud S. Aziz, provides corporate update.To the Shareholders of Genix:As the newly elected Director and President of Genix, I am pleased to provide you an update on our advancements and planned milestones. While I am certainly excited to update the important progress that Genix has made, I would first like to acknowledge the difficult...
2021-06-07 8:30 AM EDT
Genix Pharmaceuticals Corporation Enters into Exclusive License and Supply Agreement for Canada's First Generic Thyroid Medication
Vancouver, British Columbia,--(Newsfile Corp. - April 1, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") is pleased to announce that it has entered into an exclusive Canadian licensing and supply agreement (the "Agreement") with Acme Generics LLP ("ACME") for the manufacture, sale, marketing and distribution of Canada's first available generic version of Synthroid® (Levothyroxine sodium), a widely prescribed treatment for hypothyroidism. Currently sold by...
2021-04-01 8:55 AM EDT
Genix Pharmaceuticals Corporation Prepares to File Abbreviated New Drug Submissions (ANDS) for Its First Ten Ophthalmic Drugs with Health Canada
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") GENIX is pleased to announce that it has entered into an agreement with a regulatory consulting company to prepare and file Abbreviated New Drug Submissions (ANDS) with Health Canada for the first 10 of its 30 generic ophthalmic drugs, acquired by the Company.An ANDS is an application to Health Canada to approve a prescription generic pharmaceutical for...
2021-03-22 8:50 AM EDT
Genix Pharmaceuticals Corporation Announces AGM Results and Welcomes New Director
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company") announces the results of its annual general meeting of shareholders ("AGM") held in Vancouver, British Columbia on September 18, 2020.Shareholders approved all the nominees listed in the management information circular (the "Circular"), which was mailed to GENIX shareholders of record as of August 17, 2020. The following were elected to the board of...
2020-09-22 9:00 AM EDT
Genix Pharmaceuticals Corporation Announces Closing of Second Tranche Financing and Closing of Acquisition of Rights to Nutraceutical Products Sucanon(R) and Renochlor(R)
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" of the "Company") is pleased to announce that it has closed the final tranche of its non-brokered private placement financing announced in its news releases dated June 22 and June 30, 2020. Genix announced the closing for the first tranche in the amount of $640,984 by news release dated July 17th, 2020 news release. The Company has issued 2,572,667 units of the Company...
2020-08-06 10:15 AM EDT
Genix Pharmaceuticals Corporation Announces Closing of Initial Tranche of Over Subscribed Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - July 17, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce it has closed an initial tranche of $640,984 under the non-brokered private placement (the "Private Placement") announced by news release dated June 22, 2020. The Private Placement was originally announced for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. Due to strong demand, Genix filed a price reservation...
2020-07-17 3:24 PM EDT
Genix Pharmaceuticals Corporation Announces the Extension of Payment Terms for the Acquisitions of Rights to Renochlor(R), Sucanon(R) and Flu-x(TM)
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) ("GENIX" or the "Company"), announces that the Company and Canagen Pharmaceuticals Inc. ("Canagen") have mutually agreed to extend the closing dates for the payment terms ("Payment Terms") for the sole and exclusive distribution, sales and marketing rights and interest, excluding intellectual property rights, to certain nutraceutical products marketed and distributed under the brand...
2020-06-30 8:53 PM EDT
Genix Pharmaceuticals Corporation Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX) (the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") for total gross proceeds of up to $562,500, subject to a 15% over-allotment option. The Private Placement will consist of up to 3,750,000 units (excluding any over-allotment) of the Company (each a "Unit") at a price of $0.15 per Unit. Each Unit will consist of one common share of the...
2020-06-22 12:10 PM EDT
Genix Pharmaceuticals Corporation Enters into a Definitive Agreement to Acquire Global Rights to Flu-X(R)
Vancouver, British Columbia--(Newsfile Corp. - March 27, 2020) - Genix Pharmaceuticals Corporation (TSXV: GENX)("GENIX" or the "Company"), announces that it has entered into an agreement, dated for reference March 24, 2020 (the "Agreement"), with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSXV"), the Company has agreed to purchase the sole and exclusive global distribution, sales and marketing rights and interest (the...
2020-03-27 9:00 AM EDT
Genix Pharmaceuticals Corporation Completes Purchase of Rights to 30 Ophthalmic Generic Drugs and Product Dossiers
Vancouver, British Columbia--(Newsfile Corp. - February 14, 2020) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that it has completed the acquisition (the "Acquisition") of 30 World Health Organization approved ophthalmic drugs and product dossiers as stated in its press release dated December 23, 2019. Having received final acceptance to the Acquisition from the TSX Venture Exchange ("TSXV"), the Company issued 15,000,000 common shares to the shareholders...
2020-02-14 4:00 AM EST
Genix Acquires Exclusive Rights to SUCANON(R) and RENOCHLOR(R)
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2020) - Genix Pharmaceuticals Corp. (TSXV: GENX) ("GENIX" or the "Company"), announces that it has entered into an Acquisition Agreement dated for reference January 10, 2020 (the "Agreement") with Canagen Pharmaceuticals Inc. ("Canagen") pursuant to which, subject to acceptance of the TSX Venture Exchange ("TSX-V"), the Company has agreed to purchase sole and exclusive distribution, sales and marketing rights and interest (the...
2020-01-14 2:42 PM EST